Correlation Between DXC Technology and FibroGen

Can any of the company-specific risk be diversified away by investing in both DXC Technology and FibroGen at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining DXC Technology and FibroGen into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between DXC Technology and FibroGen, you can compare the effects of market volatilities on DXC Technology and FibroGen and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in DXC Technology with a short position of FibroGen. Check out your portfolio center. Please also check ongoing floating volatility patterns of DXC Technology and FibroGen.

Diversification Opportunities for DXC Technology and FibroGen

0.0

Correlation Coefficient

DXC Technology  FibroGen

Pay attention - limited upside

The 3 months correlation between DXC and FibroGen is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding DXC Technology and FibroGen in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on FibroGen and DXC Technology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on DXC Technology are associated (or correlated) with FibroGen. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of FibroGen has no effect on the direction of DXC Technology i.e., DXC Technology and FibroGen go up and down completely randomly.

Pair Corralation between DXC Technology and FibroGen

If you would invest  770.00  in FibroGen on August 30, 2024 and sell it today you would earn a total of  20.00  from holding FibroGen or generate 2.6% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Flat
Strength	Insignificant
Accuracy	98.39%
Values	Daily Returns

DXC Technology  vs.  FibroGen

DXC Technology

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days DXC Technology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental indicators, DXC Technology is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

FibroGen

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in FibroGen are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, FibroGen may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Pair Trading with DXC Technology and FibroGen

The main advantage of trading using opposite DXC Technology and FibroGen positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if DXC Technology position performs unexpectedly, FibroGen can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in FibroGen will offset losses from the drop in FibroGen's long position.

The idea behind DXC Technology and FibroGen pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.